$55.98 -$2.02 (-3.5%)

04:00 PM EST on 11/20/19

Eagle Pharmaceuticals Inc. (NASDAQ:EGRX)

CAPS Rating: 2 out of 5

Current Price $55.98 Mkt Cap $792.9M
Open $57.81 P/E Ratio 31.21
Prev. Close $58.00 Div. (Yield) $0.00 (0.0%)
Daily Range $55.57 - $58.11 Volume 160,180
52-Wk Range $38.38 - $64.94 Avg. Daily Vol. 141,370

Caps

How do you think NASDAQ:EGRX will perform against the market?

Add Stock to CAPS Watchlist

All Players

41 Outperform
4 Underperform
 

All-Star Players

9 Outperform
2 Underperform
 

Wall Street

2 Outperform
0 Underperform
 

Top NASDAQ:EGRX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

EPS100Momentum (73.78)
Submitted March 18, 2015

The next JAZZ in the making.

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:EGRX VS S&P 500 (SPY)

NASDAQ:EGRX Summary

Fools bullish on NASDAQ:EGRX are also bullish on:

Fools bearish on NASDAQ:EGRX are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about EGRX.

Recs

0
Member Avatar healthcarevalue (84.04) Submitted: 8/22/2017 11:47:27 PM : Outperform Start Price: $53.90 NASDAQ:EGRX Score: -23.31

EGRX, Eagle Pharmaceuticals, is an attractive healthcare sector stock that is undervalued at this point in time with a price earnings ratio of about nine for the last twelve trailing months, a debt/equity ratio of negligible to nothing to speak of, and a return on invested capital of over seventy for the last twelve trailing months. The stock is currently towards the lower end of its 52 week range. The company's medical products related to both oncology and critical care are high need areas for its particular set of drugs. The company's specialty pharamceutical niche sets it apart as a differentiated area for potential growth and or an attractive candidate for potential acquisition by other pharmaceutical companies wishing to expand their research and development portfolios. Its market cap of under one billion, combined with its low debt and low price/earnings ratio, make it a potentially attractive acquisition candidate.

Recs

0
Member Avatar cibient (< 20) Submitted: 4/27/2016 3:31:57 PM : Outperform Start Price: $40.16 NASDAQ:EGRX Score: -8.77

Bret Jensen - seekingalpha high conviction article on 4/22/16.

Recs

0
Member Avatar km00nster (< 20) Submitted: 4/10/2015 10:41:33 PM : Outperform Start Price: $48.89 NASDAQ:EGRX Score: -33.54

One of the fastest growing biotech stocks out there. Expecting it to outperform for the next 5-10 years.

Leaderboard

Find the members with the highest scoring picks in EGRX.

Score Leader

karakartal

karakartal (< 20) Score: +346.60

The Score Leader is the player with the highest score across all their picks in EGRX.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
Turdtwistr 58.29 2/5/2015 Outperform 5Y $19.01 +194.48% +51.66% +142.81 0 Comment
zackstracker1 21.58 2/29/2016 Underperform NS $68.08 -17.77% +59.24% +77.02 0 Comment
jmdor2222 89.25 11/2/2016 Underperform 5Y $69.64 -19.61% +47.77% +67.38 0 Comment
germanjuggler 70.17 6/10/2016 Underperform 5Y $52.81 +6.01% +47.92% +41.90 0 Comment
Bearbob63 28.74 2/19/2015 Outperform 5Y $34.67 +61.47% +48.37% +13.10 0 Comment
sojournerks 97.38 3/2/2018 Underperform 5Y $54.33 +3.05% +15.95% +12.90 0 Comment
Ander89 76.30 3/3/2015 Outperform 5Y $37.76 +48.25% +46.92% +1.33 0 Comment
NoDoughBro 70.88 3/3/2015 Outperform 5Y $37.76 +48.25% +46.92% +1.33 0 Comment
GreenAB 38.13 3/5/2015 Outperform NS $39.40 +42.08% +47.48% -5.40 0 Comment
cibient < 20 4/27/2016 Outperform 5Y $40.16 +39.39% +48.16% -8.77 1 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for EGRX.